Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 53.5 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,yervoy, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),yervoy, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),yervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),yervoy, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),yervoy in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.

Euroopa Liit - inglise - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - hiv infections - antivirals for systemic use - hard capsuleszerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.powder for oral solutionzerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 150mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 200mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 500microgram

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 1mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 20mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 50mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - abatacept - powder for solution for infusion - 250mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 300mg